Intersect Ent Inc Drug Patent Portfolio
Intersect Ent Inc owns 1 orange book drug protected by 13 US patents Given below is the list of Intersect Ent Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10232152 | Systems, devices, and method for treating a sinus condition | 24 Nov, 2034 | Active |
| US10406332 | Systems, devices, and method for treating a sinus condition | 13 Mar, 2034 | Active |
| US8763222 | Methods and devices for crimping self-expanding devices | 08 Feb, 2032 | Active |
| US10357640 | Expandable devices and methods for treating a nasal or sinus condition | 03 Oct, 2031 | Active |
| US8025635 | Device and methods for treating paranasal sinus conditions | 12 Jun, 2027 | Active |
| US7544192 | Sinus delivery of sustained release therapeutics | 29 Nov, 2026 | Active |
| US9585681 | Device and methods for treating paranasal sinus conditions | 04 Apr, 2026 | Active |
| US7662141 | Sinus delivery of sustained release therapeutics | 12 Mar, 2024 | Expired |
| US7713255 | Sinus delivery of sustained release therapeutics | 12 Mar, 2024 | Expired |
| US7951130 | Sinus delivery of sustained release therapeutics | 12 Mar, 2024 | Expired |
| US7951131 | Sinus delivery of sustained release therapeutics | 12 Mar, 2024 | Expired |
| US7951133 | Sinus delivery of sustained release therapeutics | 12 Mar, 2024 | Expired |
| US8109918 | Sinus delivery of sustained release therapeutics | 12 Mar, 2024 | Expired |
Latest Legal Activities on Intersect Ent Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Intersect Ent Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail O.P. Petition Decision | 12 Apr, 2024 | US8109918 |
|
Email Notification
Critical
| 12 Apr, 2024 | US8109918 |
| Mail-Record Petition Decision of Granted to Make Entity Status large | 09 Apr, 2024 | US8109918 |
| O.P. Petition Decision | 08 Apr, 2024 | US8109918 |
| Record Petition Decision of Granted to Make Entity Status large | 08 Apr, 2024 | US8109918 |
| Petition Entered | 13 Feb, 2024 | US8109918 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 13 Feb, 2024 | US8109918 |
| Payment of Maintenance Fee under 1.28(c) | 13 Feb, 2024 | US8109918 |
|
Email Notification
Critical
| 09 Feb, 2024 | US8109918 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 09 Feb, 2024 | US8109918 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 21 Jul, 2023 | US8109918 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Feb, 2023 | US10406332 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Feb, 2023 | US8025635 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 15 Feb, 2023 | US10406332 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 15 Feb, 2023 | US8025635 |
Intersect Ent Inc's Family Patents
Intersect Ent Inc drugs have patent protection in a total of 12 countries. It has a significant patent presence in the US with 51.2% of its patents being US patents. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Intersect Ent Inc Drug List
Given below is the complete list of Intersect Ent Inc's drugs and the patents protecting them.
1. Sinuva
Sinuva is protected by 13 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10232152 | Systems, devices, and method for treating a sinus condition |
24 Nov, 2034
(10 years from now)
| Active |
| US10406332 | Systems, devices, and method for treating a sinus condition |
13 Mar, 2034
(9 years from now)
| Active |
| US8763222 | Methods and devices for crimping self-expanding devices |
08 Feb, 2032
(7 years from now)
| Active |
| US10357640 | Expandable devices and methods for treating a nasal or sinus condition |
03 Oct, 2031
(6 years from now)
| Active |
| US8025635 | Device and methods for treating paranasal sinus conditions |
12 Jun, 2027
(2 years from now)
| Active |
| US7544192 | Sinus delivery of sustained release therapeutics |
29 Nov, 2026
(2 years from now)
| Active |
| US9585681 | Device and methods for treating paranasal sinus conditions |
04 Apr, 2026
(1 year, 4 months from now)
| Active |
| US7662141 | Sinus delivery of sustained release therapeutics |
12 Mar, 2024
(8 months ago)
| Expired |
| US7713255 | Sinus delivery of sustained release therapeutics |
12 Mar, 2024
(8 months ago)
| Expired |
| US7951130 | Sinus delivery of sustained release therapeutics |
12 Mar, 2024
(8 months ago)
| Expired |
| US7951131 | Sinus delivery of sustained release therapeutics |
12 Mar, 2024
(8 months ago)
| Expired |
| US7951133 | Sinus delivery of sustained release therapeutics |
12 Mar, 2024
(8 months ago)
| Expired |
| US8109918 | Sinus delivery of sustained release therapeutics |
12 Mar, 2024
(8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sinuva's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List